Data Provided by Refinitiv. Minimum 15 minutes delayed.
Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents that may harness the patient’s immune system to combat and eradicate cancer. Sotigalimab, our lead asset which is in Phase 2 development, as well as our expanding antibody therapeutic pipeline, were discovered using Apexigen’s proprietary APXiMAB™ platform. This unique platform has enabled the discovery and development of high-quality therapeutic antibodies against a variety of molecular targets, including targets that are difficult to drug with conventional antibody technologies. Currently, one APXiMAB platform candidate is commercially available; the others are advancing through clinical development, either internally or through several licensees with our collaboration partners. Apexigen is headquartered in San Carlos, California.